We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 188 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 188 → 0 (-188)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.49B → $0 (-$1.49B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 188

Holders
–
Holders Change
-188
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
188
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$143M
2
BlackRock
BlackRock
New York
-$129M
3
PCM
Pentwater Capital Management
Florida
-$86.2M
4
Goldman Sachs
Goldman Sachs
New York
-$75.8M
5
AAM
Alpine Associates Management
Florida
-$71.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
51
Two Sigma Investments
New York
– -$5.27M -152,876 Closed
GCL
52
Glazer Capital LLC
New York
– -$5.17M -150,000 Closed
Norges Bank
53
Norges Bank
Norway
– -$5M -145,222 Closed
SC
54
Sculptor Capital
New York
– -$4.99M -144,900 Closed
Barclays
55
Barclays
United Kingdom
– -$4.61M -133,703 Closed
SCS
56
Syquant Capital SAS
France
– -$4.33M -125,547 Closed
PPA
57
Parametric Portfolio Associates
Washington
– -$4.31M -125,235 Closed
SG Americas Securities
58
SG Americas Securities
New York
– -$4.23M -122,812 Closed
Hudson Bay Capital Management
59
Hudson Bay Capital Management
Connecticut
– -$4.02M -116,700 Closed
WAM
60
Wolverine Asset Management
Illinois
– -$3.99M -115,812 Closed
EPM
61
Equitec Proprietary Markets
Illinois
– -$3.58M -103,800 Closed
UBS Group
62
UBS Group
Switzerland
– -$3.42M -99,157 Closed
California Public Employees Retirement System
63
California Public Employees Retirement System
California
– -$3.32M -96,400 Closed
Swiss National Bank
64
Swiss National Bank
Switzerland
– -$3.31M -96,174 Closed
Jane Street
65
Jane Street
New York
– -$3.13M -90,855 Closed
PP
66
Paloma Partners
Connecticut
– -$3.13M -90,749 Closed
BCM
67
Beryl Capital Management
California
– -$3.12M -90,498 Closed
SMC
68
S. Muoio & Co
New York
– -$3.1M -90,000 Closed
TRCT
69
Tower Research Capital (TRC)
New York
– -$2.66M -77,282 Closed
KC
70
Kellner Capital
New York
– -$2.64M -76,600 Closed
Citadel Advisors
71
Citadel Advisors
Florida
– -$2.6M -75,551 Closed
WBC
72
Westpac Banking Corp
Australia
– -$2.54M -73,860 Closed
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
– -$2.42M -70,264 Closed
Deutsche Bank
74
Deutsche Bank
Germany
– -$2.38M -69,244 Closed
Capstone Investment Advisors
75
Capstone Investment Advisors
New York
– -$2.37M -68,692 Closed
1 2
3
4 5

AIMT Hedge Fund Activity: Q4 2020 in Review

0 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2020, worth a combined $0 — down 100% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 188 funds closed out of AIMT and 0 opened new positions — a net loss of 188 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $143M sold.

  • 0 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2020, down from 188 in Q3 2020.
  • Funds reported $0 of Aimmune Therapeutics stock for Q4 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Aimmune Therapeutics positions in Q4 2020 and 188 closed out, a net change of -188 holders.
  • The largest Aimmune Therapeutics seller in Q4 2020 was Vanguard Group, an estimated $143M sold.

Based on aggregated 13F filings for Q4 2020.